Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, October 2007, p. 3531-3536, Vol. 51, No. 10
0066-4804/07/$08.00+0 doi:10.1128/AAC.00503-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Pseudomonas aeruginosa May Accumulate Drug Resistance Mechanisms without Losing Its Ability To Cause Bloodstream Infections
Didier Hocquet,1*
Philippe Berthelot,2
Micheline Roussel-Delvallez,3
Roger Favre,4
Katy Jeannot,1
Odile Bajolet,5
Nicole Marty,6
Florence Grattard,2
Patricia Mariani-Kurkdjian,7
Edouard Bingen,7
Marie-Odile Husson,3
Gérard Couetdic,1 and
Patrick Plésiat1
Centre National de Référence Résistance aux Antibiotiques: Pseudomonas aeruginosa, Hôpital Jean Minjoz, Besançon,1
Laboratoire de Bactériologie-Virologie, Hôpital Nord, Saint Etienne,2
Laboratoire de Bactériologie, Hôpital Calmette, Lille,3
Laboratoire de Microbiologie Clinique, Hôpital d'Instruction des Armées Bégin, Saint-Mandé,4
Laboratoire de Bactériologie-Hygiène, Hôpital Robert Debré, Reims,5
Laboratoire de Bactériologie-Hygiène, Hôpital Rangueil, Toulouse,6
Laboratoire de Microbiologie, Hôpital Robert Debré, Paris, France7
Received 13 April 2007/
Returned for modification 4 May 2007/
Accepted 25 July 2007
In this study, we systematically investigated the resistance mechanisms to ß-lactams, aminoglycosides, and fluoroquinolones of 120 bacteremic strains of Pseudomonas aeruginosa. Pulsed-field gel electrophoresis genotyping showed that 97 of these strains were represented by a single isolate, 10 by 2 and 1 by 3 clonally related isolates, respectively. Seventy-five percent (90 out of 120) of the bacteremic P. aeruginosa strains displayed a significant resistance to one or more of the tested antimicrobials (up to 11 for 1 strain). These strains were found to harbor a great diversity of resistance mechanisms (up to 7 in 1 strain), leading to various levels of drug resistance. Interestingly, 11 and 36% of the isolates appeared to overproduce the MexAB-OprM and MexXY-OprM efflux systems, respectively. Altogether, our results show that P. aeruginosa may accumulate intrinsic (overproduction of cephalosporinase AmpC, increased drug efflux, fluoroquinolone target mutations, and deficient production of porin OprD) and exogenous (production of secondary ß-lactamases and aminoglycoside-modifying enzymes) resistance mechanisms without losing its ability to generate severe bloodstream infections. Consequently, clinicians should be aware that multidrug-resistant P. aeruginosa may remain fully pathogenic.
* Corresponding author. Mailing address: Centre National de Référence Résistance aux antibiotiques:
Pseudomonas aeruginosa, Hôpital Jean Minjoz, 25030 Besançon, Cedex, France. Phone: (33) 3 81 66 82 86. Fax: (33) 3 81 66 89 14. E-mail:
dhocquet{at}chu-besancon.fr
Published ahead of print on 6 August 2007.
Antimicrobial Agents and Chemotherapy, October 2007, p. 3531-3536, Vol. 51, No. 10
0066-4804/07/$08.00+0 doi:10.1128/AAC.00503-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Tam, V. H., Chang, K.-T., Abdelraouf, K., Brioso, C. G., Ameka, M., McCaskey, L. A., Weston, J. S., Caeiro, J.-P., Garey, K. W.
(2010). Prevalence, Resistance Mechanisms, and Susceptibility of Multidrug-Resistant Bloodstream Isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother.
54: 1160-1164
[Abstract]
[Full Text]
-
Moya, B., Zamorano, L., Juan, C., Perez, J. L., Ge, Y., Oliver, A.
(2010). Activity of a New Cephalosporin, CXA-101 (FR264205), against {beta}-Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients. Antimicrob. Agents Chemother.
54: 1213-1217
[Abstract]
[Full Text]
-
Juan, C., Zamorano, L., Perez, J. L., Ge, Y., Oliver, A., on Behalf of the Spanish Group for the Study of Ps,
(2010). Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical Strains. Antimicrob. Agents Chemother.
54: 846-851
[Abstract]
[Full Text]
-
Viedma, E., Juan, C., Acosta, J., Zamorano, L., Otero, J. R., Sanz, F., Chaves, F., Oliver, A.
(2009). Nosocomial Spread of Colistin-Only-Sensitive Sequence Type 235 Pseudomonas aeruginosa Isolates Producing the Extended-Spectrum {beta}-Lactamases GES-1 and GES-5 in Spain. Antimicrob. Agents Chemother.
53: 4930-4933
[Abstract]
[Full Text]
-
Vettoretti, L., Plesiat, P., Muller, C., El Garch, F., Phan, G., Attree, I., Ducruix, A., Llanes, C.
(2009). Efflux Unbalance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients. Antimicrob. Agents Chemother.
53: 1987-1997
[Abstract]
[Full Text]
-
Moya, B., Juan, C., Alberti, S., Perez, J. L., Oliver, A.
(2008). Benefit of Having Multiple ampD Genes for Acquiring {beta}-Lactam Resistance without Losing Fitness and Virulence in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.
52: 3694-3700
[Abstract]
[Full Text]
-
Jeannot, K., Elsen, S., Kohler, T., Attree, I., van Delden, C., Plesiat, P.
(2008). Resistance and Virulence of Pseudomonas aeruginosa Clinical Strains Overproducing the MexCD-OprJ Efflux Pump. Antimicrob. Agents Chemother.
52: 2455-2462
[Abstract]
[Full Text]
-
Hocquet, D., Muller, A., Blanc, K., Plesiat, P., Talon, D., Monnet, D. L., Bertrand, X.
(2008). Relationship between Antibiotic Use and Incidence of MexXY-OprM Overproducers among Clinical Isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother.
52: 1173-1175
[Abstract]
[Full Text]